On Jan. 16, 2002, both drug prices rose to $41.74. For years, drug companies that say they are in fierce competition with one another also have raised their list prices nearly in sync. sent a letter to the Department of Justice requesting an investigation into possible collusion between drug companies that make insulin. The drugmakers have argued that they are raising the prices to increase the rebates given to companies that bargain for drug prices on behalf of insurers. Eli Lilly, Novo Nordisk and Sanofi, the three companies that dominate the insulin market, all said there was no collusion in insulin pricing.

Source: Washington Post November 03, 2016 22:08 UTC